Regeneron and Sanofi Provide Update on Ongoing Dupixent® (dupilumab) Chronic Spontaneous Urticaria Phase 3 Program February 18, 2022 In this article: | Analyst Report: Regeneron Phars, Inc TARRYTOWN, N.Y. and PARIS, Feb. 18, 2022 /PRNewswire/ -- In a Phase 3 trial in patients refractory to omalizumab, Dupixent did not reach statistical significance in interim analysis despite numeric improvements observed across key endpoints; trial will be stopped due to futility Positive results from a previous Phase 3 trial in biologic-naïve patients showed Dupixent significantly reduced itch and hives compared to standard-of-care antihistamines alone Companies remain committed to advancing Dupixent for patients with chronic spontaneous urticaria uncontrolled on antihistamines and are evaluating next steps Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced a Phase 3 trial (CUPID STUDY B) evaluating Dupixent® (dupilumab) in patients with chronic spontaneous urticaria (CSU) will stop due to futility, based on a pre-specified interim analysis. The trial, which assessed Dupixent added to antihistamines in patients refractory to omalizumab at 24 weeks, showed positive numerical trends in reducing itch and hives (the primary endpoints) but did not meet statistical significance during an interim analysis conducted by an independent review committee. The safety data were generally consistent with the known safety profile of Dupixent in its approved indications. The LIBERTY-CUPID pivotal program was initiated in 2020 with an accelerated direct-to-Phase 3 strategy. The previously reported Phase 3 trial, which evaluated a different group of patients who were biologic-naïve (i.e., not previously treated with omalizumab), met its primary and all key secondary endpoints at 24 weeks, showing that adding Dupixent to standard-of-care antihistamines significantly reduced itch and hives compared to antihistamines alone. The companies remain committed to advancing Dupixent for patients with CSU uncontrolled on antihistamines and are evaluating next steps. Chronic spontaneous urticaria is a very complex disease, and these data add to the body of evidence assessing the underlying drivers of disease burden, including the potential role of interleukin-4 and interleukin-13, said George D. Yancopoulos, M.D., Ph.D., President and Chief Scientific Officer at Regeneron. While Dupixent did not show a significant benefit in the most difficult-to-treat patients who remain refractory to all approved medicines, we are carefully assessing the potential role of Dupixent in CSU based on the success of the first Phase 3 trial in biologic-naïve patients, where Dupixent nearly doubled the reduction in itch and urticaria activity. Detailed results from the first trial will be presented at the AAAAI Annual Meeting later this month, and the companies expect to share results from the second trial in a scientific forum. Regeneron and Sanofi are rapidly advancing a broad clinical development program to evaluate Dupixent in diseases with significant unmet need and where type 2 inflammation may play a role. The companies also recently announced positive Phase 3 results in eosinophilic esophagitis (EoE) and prurigo nodularis (PN), and additional results are also expected later this year in pediatric EoE, chronic inducible urticaria-cold (CindU), and hand and foot atopic dermatitis. Regeneron©M赛诺µá´£¨Ñ¥¿¦b进¦æªºDupixent®¡]dupilumab¡^ºC©Ê¦Û发©Ê荨³Â¯l3´Á计¦Eªº³Ì·s±¡úG 2022¦~2¤ë18¤é ¦b这½g¤å³¹¤¤¡C | ¤ÀªR师报§i¡CRegeneron Phars, Inc 纽约¦{¶ð¨½§J镇©M¤Ú¾¤2022¦~2¤ë18¤é电 /¬ü³qªÀ/ -- ¦b¤@项针对奥马¯]单§Ü难ªv©Ê±wªÌªº3´Á试验¤¤¡A尽ºÞ¦b关键终点¤W观¹î¨ì数¦r¤Wªº§ïµ½¡A¦ýDupixent¦b¤¤´Á¤ÀªR¤¤¥¼达¨ì统计学·Núå¡F试验将¦]ÆӮĦӰ±¤î¡C ¤§«e¦b¥Íª«¨î剂ÆӮıwªÌ¤¤进¦æªº¤@项3´Á试验ªº积Ìå结ªG显¥Ü¡AÉO单独¨Ï¥Î标ã§Ü组Ói药¬Û¤ñ¡ADupixent¯à显µÛú£¤Öæ±Ö}©M荨³Â¯l¡C ¤½¥q¤´P¤O¤_±À动Dupixent¥Î¤_§Ü组Ói药ÆÓªk±±¨îªººC©Ê¦Û发©Ê荨³Â¯l±wªÌ¡A¦}¥¿¦b评¦ô¤U¤@¨B¦æ动¡C Regeneron¨î药¤½¥q¡]纳´µ达§J¡GREGN¡^©M赛诺µá¤½¥q¤µ¤Ñ«Å¥¬¡A®ÚÕu预¥ý«ü©wªº¤¤´Á¤ÀªR¡A评¦ôDupixent®¡]dupilumab¡^对ºC©Ê¦Û发©Ê荨³Â¯l¡]CSU¡^±wªÌªº3´Á试验¡]CUPID STUDY B¡^将¦]ÆӮĦӰ±¤î¡C该试验评¦ô¤F对奥马¯]单§Ü难ªvªº±wªÌ¦b24©P内将Dupixent²K¥[¨ì§Ü组Ói药ª«¤¤¡A¦bú£¤Öæ±Ö}©M荨³Â¯l¡]¥Dn终点¡^¤è±显¥Ü¥X积Ì媺数¦r趋势¡A¦ý¦b独¥ß审¬d©e员会进¦æªº¤¤´Á¤ÀªR¤¤没¦³达¨ì统计·Núå¡C¦w¥þ©Ê数ÕuÉODupixent¦b¨ä§å㪺Óì应¯g¤¤ªº¤wª¾¦w¥þ©Ê¯S©º°ò¥»¤@P¡C LIBERTY-CUPID枢轴项¥Ø¤_2020¦~ûD动¡Aªö¨ú¤F¥[³tª½±µ进¤J3´Áªºµ¦²¤¡C¤§«e报¹Dªº3´Á试验评¦ô¤F¤£¦Pªº¥Íª«¨î剂ÆӮıwªÌ¸sÊ^¡]§Y¤§«e没¦³±µ¨ü过奥马¯]单§Üªv疗¡^¡A¦b24©P时达¨ì¤F¨ä¥Dn©M©Ò¦³关键ªº¦¸n终点¡Aªí©úÉO单独¨Ï¥Î§Ü组Ói药ª«¬Û¤ñ¡A¦b标ã护²z§Ü组Ói药ª«¤¤²K¥[Dupixent¥i显µÛú£¤Öæ±Ö}©M荨³Â¯l¡C两®a¤½¥q¤´µMP¤O¤_±À动Dupixent¥Î¤_¨Ï¥Î§Ü组Ói药ÆÓªk±±¨îªºCSU±wªÌ¡A¦}¥¿¦b评¦ô¤U¤@¨B¦æ动¡C Regeneron¤½¥q总µôݺ®u¬ì学©xGeorge D. Yancopoulos³Õ¤h说¡GºC©Ê¦Û发©Ê荨³Â¯l¬O¤@Ïú«D±`Î`杂ªº¯e¯f¡A这¨Ç数Õu¼W¥[¤F评¦ô¯e¯f负ü®ýͦb驱动¦]¯Àªº证Õu¡A¥]¬A¥Õ细M¤¶¯À4©M¥Õ细M¤¶¯À13ªºýͦb§@¥Î¡C虽µMDupixent¦b对©Ò¦³获§å药ª«¤´难ªv¦nªº³Ì难ªv¦nªº¯f¤H¨¤W没¦³显¥Ü¥X©ú显ªº¦n处¡A¦ý§Ú们¥¿¦b¥J细评¦ôDupixent¦bCSU¤¤ªºýͦb§@¥Î¡A这¬O°ò¤_¦b¥Íª«¨î剂ÆӮĪº¯f¤H¨¤W进¦æªº²Ä¤@个3´Á试验ªº¦¨¥\¡ADupixent¨Ïæ±Ö}©M荨³Â¯l¬¡动ªºú£¤Ö¤L¥G½¤F¤@µf¡C ²Ä¤@¦¸试验ªº详细结ªG将¦b¥»¤ë±ß¨Ç时ÔªºAAAAI¦~会¤W¤½¥¬¡A两®a¤½¥q预计将¦b¤@个¬ì学论坛¤W¤À¨É²Ä¤G¦¸试验ªº结ªG¡CRegeneron©M赛诺µá¥¿¦b¨³³t±À进¤@项ÆΪxªº临§É开发计¦E¡A¥H评¦ôDupixent¦b¦³«¤j¥¼满¨¬»Ý¨Dªº¯e¯f¤¤ªº§@¥Î¡A¥H¤Î2«¬ª¢¯g¥i¯à发挥ªº§@¥Î¡C这两®a¤½¥q³Ìªñ还«Å¥¬¤F¶Ý»Ä细M©Ê¹ºÞª¢¡]EoE¡^©M结节©Êæ±Ö}¯g¡]PN¡^ªº3´Á阳©Ê结ªG¡A预计¤µ¦~±ß¨Ç时Ô¦b¤p¤IEoE¡BºC©Ê诱导©Ê荨³Â¯l-·P«_¡]CindU¡^©M¤â¨¬Éݦì©Ê¥Öª¢¤è±¤]会¦³§ó¦h结ªG¡C |